Michael E. Abram

5.5k citations

36 papers · 1.6k indexed · 1 hit paper · h-index 20

Impact in

Virology top 1%
- HIV Research and Treatment
Infectious Diseases top 1%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Virology 21
- HIV Research and Treatment 21
Infectious Diseases 27
- HIV/AIDS drug development and treatment 24
- HIV/AIDS Research and Interventions 11

Co-authors: Andrea L. Ferris (2 shared papers)Andrew Cheng (10 shared papers)W. Gregory Alvord (2 shared papers)Stephen H. Hughes (2 shared papers)Wei Shao (2 shared papers)Michael A. Parniak (3 shared papers)Marshall W. Fordyce (6 shared papers)Kirsten White (8 shared papers)
Journals: JAIDS Journal of Acquired Immune Deficiency Syndromes (7 papers)Journal of Virology (4 papers)HIV Clinical Trials (4 papers)Antimicrobial Agents and Chemotherapy (3 papers)Molecular Pharmacology (2 papers)
Partner nations: United States United Kingdom France

In The Last Decade

Michael E. Abram

36 papers receiving 1.5k citations

Hit Papers

align trajectories log scale

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants 2023 · 70 citations

Peers

Countries citing papers authored by Michael E. Abram

Since Specialization

Citations

This map shows the geographic impact of Michael E. Abram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Abram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Abram more than expected).

Fields of papers citing papers by Michael E. Abram

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Abram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Abram. The network helps show where Michael E. Abram may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael E. Abram, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael E. Abram Line = papers co-authored together Michael E. Abram links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication Journal of Virology ·Michael E. Abram, Andrea L. Ferris, Wei Shao, W. Gregory Alvord, Stephen H. Hughes	2010	188
2	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anton Pozniak, José Ramón Arribas, Joseph Gathe, Samir K. Gupta, Frank A. Post, Mark Bloch, Anchalee Avihingsanon, Gordon Crofoot, Paul Benson, Kenneth Lichtenstein, Moti Ramgopal, Ploenchan Chetchotisakd, Joseph M. Custodio, Michael E. Abram, Xuelian Wei, Andrew Cheng, Scott McCallister, Devi SenGupta, Marshall W. Fordyce	2015	158
3	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial The Lancet HIV ·Joel E. Gallant, Eric S. Daar, François Raffi, Cynthia Brinson, Peter Ruane, Edwin DeJesus, Margaret Johnson, Nathan Clumeck, Olayemi Osiyemi, D Ward, Javier O Morales-Ramirez, Mingjin Yan, Michael E. Abram, Andrew Plummer, Andrew Cheng, Martin S. Rhee	2016	127
4	Differential Polymerase Activity in Avian and Mammalian Cells Determines Host Range of Influenza Virus Journal of Virology ·Gülşah Gabriel, Michael E. Abram, Bjoern Keiner, Ralf Wagner, Hans‐Dieter Klenk, Jürgen Stech	2007	105
5	A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jürgen K. Rockstroh, Edwin DeJesus, Keith Henry, Jean‐Michel Molina, Joseph Gathe, S. Ramanathan, Xuelian Wei, Andrew Plummer, Michael E. Abram, Andrew Cheng, Marshall W. Fordyce, Javier Szwarcberg	2013	97
6	Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness Antimicrobial Agents and Chemotherapy ·Michael E. Abram, Rebecca Hluhanich, Derrick Goodman, Kristen Andreatta, Nicolas Margot, Linda Ye, Anita Niedziela‐Majka, Tiffany Barnes, Nikolai Novikov, Xiaowu Chen, Evguenia S. Svarovskaia, Damian J. McColl, Kirsten White, Michael D. Miller	2013	94
7	Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017−2018 INFORM-RSV Study Journal of Clinical Microbiology ·David E. Tabor, Fiona Fernandes, Annefleur C Langedijk, Deidre Wilkins, Robert Jan Lebbink, Andrey Tovchigrechko, Alexey Ruzin, Leyla Kragten‐Tabatabaie, Hong Jin, Mark T. Esser, Louis Bont, Michael E. Abram	2020	73
8	Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences BMC Genomics ·Áine O’Toole, Oliver G. Pybus, Michael E. Abram, Elizabeth J. Kelly, Andrew Rambaut	2022	71
9	Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants Nature Medicine ·Deidre Wilkins, Yuan Yuan, Yue Chang, Anastasia A. Aksyuk, Beatriz Seoane Núñez, Ulrika Wählby Hamrén, Tianhui Zhang, Michael E. Abram, Amanda Leach, Tonya Villafana, Mark T. Esser Hit paper breakdown →	2023	70
10	Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults JAIDS Journal of Acquired Immune Deficiency Syndromes ·François Raffi, Chloe Orkin, Amanda Clarke, Laurence Slama, Joel E. Gallant, Eric S. Daar, Keith Henry, Jorge Santana‐Bagur, David Stein, Nicholaos Bellos, Anthony Scarsella, Mingjin Yan, Michael E. Abram, Andrew Cheng, Martin S. Rhee	2017	60
11	Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study JAIDS Journal of Acquired Immune Deficiency Syndromes ·Frank A. Post, Pablo Tebas, Amanda Clarke, Laurent Cotte, William R. Short, Michael E. Abram, Shuping Jiang, Andrew Cheng, Moupali Das, Marshall W. Fordyce	2016	53
12	The Catalytic DNA Topoisomerase II Inhibitor Dexrazoxane (ICRF-187) Induces Differentiation and Apoptosis in Human Leukemia K562 Cells Molecular Pharmacology ·Brian B. Hasinoff, Michael E. Abram, Norman Barnabé, Tayeb Khélifa, William P. Allan, Jack C. Yalowich	2001	50
13	Virion Instability of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Mutated in the Protease Cleavage Site between RT p51 and the RT RNase H Domain Journal of Virology ·Michael E. Abram, Michael A. Parniak	2005	48
14	Mutations in HIV-1 Reverse Transcriptase Affect the Errors Made in a Single Cycle of Viral Replication Journal of Virology ·Michael E. Abram, Andrea L. Ferris, Kalyan Das, Octavio A. Quiñones, Wei Shao, Steven Tuske, W. Gregory Alvord, Eddy Arnold, Stephen H. Hughes	2014	43
15	Mutational Analysis of Tyr-501 of HIV-1 Reverse Transcriptase Journal of Biological Chemistry ·Dominique Arion, Nicolas Sluis‐Cremer, Kyung‐Lyum Min, Michael E. Abram, Ronald S. Fletcher, Michael A. Parniak	2002	42
16	Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide The Journal of Infectious Diseases ·Nicolas Margot, Pamela Wong, Rima Kulkarni, Kirsten White, Danielle Porter, Michael E. Abram, Christian Callebaut, Michael D. Miller	2017	31
17	The Rise of Seniority in the House of Representatives Polity ·Michael E. Abram, Joseph Cooper	1968	29
18	Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial HIV Clinical Trials ·Frank A. Post, Yazdan Yazdanpanah, Gabriel Schembri, Adriano Lazzarin, Jacques Reynes, Franco Maggiolo, Mingjin Yan, Michael E. Abram, Cecilia Tran‐Muchowski, Andrew Cheng, Martin S. Rhee	2017	24
19	Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients HIV Clinical Trials ·Rima Kulkarni, Michael E. Abram, Damian J. McColl, Tiffany Barnes, Marshall W. Fordyce, Javier Szwarcberg, Andrew Cheng, Michael D. Miller, Kirsten White	2014	21
20	The Catalytic DNA Topoisomerase II Inhibitor Dexrazoxane (ICRF-187) Induces Endopolyploidy in Chinese Hamster Ovary Cells Journal of Pharmacology and Experimental Therapeutics ·Brian B. Hasinoff, Michael E. Abram, Gaik‐Lean Chee, Erwin Huebner, E H Byard, Norman Barnabé, V J Ferrans, Zu‐Xi Yu, Jack C. Yalowich	2000	19

About Michael E. Abram

Michael E. Abram is a scholar working on Virology, Infectious Diseases, Emergency Medicine, Transplantation and Toxicology, having authored 36 papers that have together received 1.6k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (24 papers), HIV Research and Treatment (21 papers), HIV/AIDS Research and Interventions (11 papers), HIV-related health complications and treatments (7 papers), Pharmacological Effects and Toxicity Studies (4 papers), Cancer therapeutics and mechanisms (3 papers), Biochemical and Molecular Research (3 papers) and Respiratory viral infections research (3 papers). The work is most often cited by research in Virology (751 citations), Infectious Diseases (1.1k citations), Emergency Medicine (276 citations), Epidemiology (431 citations) and Hepatology (79 citations). Michael E. Abram has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Andrea L. Ferris, Andrew Cheng, W. Gregory Alvord, Stephen H. Hughes, Wei Shao, Michael A. Parniak, Marshall W. Fordyce, Kirsten White, Nicolas Margot and Ralf Wagner. Their work appears in journals such as JAIDS Journal of Acquired Immune Deficiency Syndromes, Journal of Virology, HIV Clinical Trials, Antimicrobial Agents and Chemotherapy and Molecular Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact